France Medical Devices Market Report 2026: LPP Listing, ANSM Regulation, and Hospital Procurement Intelligence

The French medical devices market is estimated at EUR 14–16 billion in 2026, making it the third-largest medical device market in the EU after Germany and the UK. France has approximately 3,000 hospitals and clinics, 74,000 pharmacies, and a strong tradition of medical device innovation through companies including Laboratoires Urgo, Vygon, and Coloplast France. The market is segmented between hospital procurement (approximately 60%) and outpatient/community care (40%). Private clinic groups (Elsan, Ramsay Santé, Almaviva Santé) represent a growing procurement channel alongside the public AP-HP (Assistance Publique-Hôpitaux de Paris) and regional CHU (Centre Hospitalier Universitaire) networks. Growth is underpinned by an ageing population, rising adoption of minimally invasive and robotic surgery, and government-backed digital health investment through the Ségur du Numérique en Santé programme, all of which are expanding the addressable device categories beyond traditional consumables and implants.

ANSM (Agence nationale de sécurité du médicament et des produits de santé) is France's national competent authority for medical devices under EU MDR 2017/745 and IVDR 2017/746. CE marking via an EU Notified Body is required for Class IIa, IIb, and III devices. ANSM conducts post-market surveillance, manages the French vigilance system (signalement incidents), and contributes to EMA Notified Body oversight. ANSM operates a dedicated medical device registration system (DMDIV for IVDs) and runs ANSM medical device warning communications. For clinical investigations, French ethics committees (CPP, Comités de Protection des Personnes) are required alongside ANSM authorisation. France's own LNE/G-MED is among the EU's MDR-designated Notified Bodies, though ongoing Notified Body capacity constraints across the EU continue to extend certification timelines for manufacturers transitioning legacy MDD certificates to full MDR compliance.

Medical devices eligible for Assurance Maladie reimbursement must be listed on the LPP (Liste des Produits et Prestations). The LPP is maintained by the CNAM and managed through HAS assessment. HAS CNEDIMTS (Commission nationale d'évaluation des dispositifs médicaux et des technologies de santé) evaluates the ASA (added value in medical service rendered) of new devices seeking LPP listing. The ASA level determines the reimbursement tariff. Hospital devices used within DRG-funded procedures are typically financed within the GHS (Groupement Homogène de Séjours) tariff, though the LPPR/LPP lists hospital-specific high-cost implants that receive separate add-on payment. LPP listings are not permanent: CNEDiMTS periodically re-evaluates registered devices, typically on a roughly five-year cycle, and can revise, narrow, or withdraw a listing if updated clinical evidence no longer supports the original ASA level.

Forfait Innovation (FI) is France's early access pathway for genuinely innovative medical devices that cannot be adequately reimbursed within existing DRG or LPP frameworks. Under FI, innovative devices can receive temporary conditional reimbursement while real-world evidence is collected in French hospitals. The program requires HAS designation as "innovative" and evidence generation commitments from the manufacturer. Forfait Innovation has covered advanced surgical robotics, novel cardiac devices, and precision diagnostics. It is the key market access pathway for novel medtech seeking rapid French hospital access before full LPP listing. A parallel route, RIHN (Référentiel des Actes Innovants Hors Nomenclature), performs a similar temporary-listing function specifically for innovative in vitro diagnostic tests ahead of their eventual inclusion on the standard laboratory nomenclature.

GHT (Groupements Hospitaliers de Territoire) are territorial hospital groups introduced by the Loi de Modernisation du Système de Santé (2016), pooling procurement, clinical protocols, and administrative functions across public hospitals in a defined territory. France has approximately 135 GHTs, each coordinating device procurement for their member hospitals. GHT lead purchasing hospitals negotiate framework contracts on behalf of their entire group. This consolidation means that securing a GHT contract provides access to multiple hospital sites simultaneously — making GHT lead hospital tender decisions critical commercial milestones for device manufacturers. Smaller and mid-sized device manufacturers, in particular, need to identify and engage the GHT's lead pharmacy or biomedical engineering department early, since a missed GHT-level framework cycle can effectively close off a territory's public hospitals for several years.

Materiovigilance is France's medical device post-market safety surveillance system, coordinated by ANSM under the vigilance obligations set out in EU MDR Articles 87-92. Regional and hospital-based materiovigilance correspondents (correspondants locaux de matériovigilance) collect and escalate device-related incidents to ANSM, which assesses whether corrective action — including a field safety corrective action (FSCA) or a product recall — is warranted. Manufacturers and their EU authorised representatives must report serious incidents to ANSM within the statutory timelines defined under MDR vigilance rules, and ANSM periodically publishes device safety alerts and recall notices. ANSM also feeds into the EU-wide EUDAMED vigilance module to coordinate cross-border safety signals with other member state competent authorities. For manufacturers, maintaining an active relationship with materiovigilance correspondents at target hospitals is an often underestimated but commercially important compliance requirement.

UniHA (Union des Hôpitaux pour les Achats) is France's largest hospital group purchasing organisation, pooling procurement volume across more than 1,000 public hospitals and negotiating framework agreements spanning pharmaceuticals, medical devices, and hospital equipment. UniHA runs centralised, multi-year tenders for device categories including orthopaedic implants, cardiovascular consumables, surgical instruments, and diagnostic equipment, with framework agreements typically running three to four years. Winning a UniHA framework agreement can open simultaneous commercial access to hundreds of member hospitals, making UniHA's tender calendar a critical planning input for device manufacturers targeting the French public hospital sector. Alongside UniHA, RESAH (Réseau des Acheteurs Hospitaliers) and individual GHT lead-hospital tenders provide additional group purchasing routes, particularly for mid-sized hospital groups and specialised device categories that fall outside UniHA's national lots.

BioNixus delivers medical device market research in france: regulator-aware access intelligence, hospital consumption analogues, physician and payer qualitative programmes, and launch evidence under EphMRA and BHBIA governance with GDPR-aligned fieldwork for multinational sponsors. Teams receive decision-ready outputs validated against national policy and institution-level adoption—not desk extrapolation from unrelated regions.

BioNixus supports france-based medical device companies expanding into GCC and MENA markets with SFDA and MOHAP regulatory intelligence, NUPCO and hospital procurement tracking in Saudi Arabia, UAE insurer and formulary research, physician panels across GCC countries, and comparative france versus GCC market intelligence. GCC expansion is a distinct service line with its own tender and access calendars—see our GCC pharmaceutical market report for regional context. Launch assumptions should be validated market by market rather than from a single Gulf average.